EWTX — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-06

• Since our inception in 2017, we have applied our deep expertise in muscle biology and small molecule drug discovery to build a proprietary precision medicine platform. This foundation has generated multiple clinical and preclinical programs across skeletal and cardiac muscle, including sevasemten fo…

• Following this transaction, Edgewise is positioned as a cardiovascular-focused late-stage clinical biopharmaceutical company advancing therapies for people living with serious cardiovascular diseases. Our lead cardiovascular program, EDG-7500, is a novel, oral, selective cardiac sarcomere modulator …

• The following table summarizes our results of operations for the three months ended June 30, 2026 and 2025:

• Research and development expenses were $47.5 million and $33.6 million for the three months ended June 30, 2026 and 2025, respectively. The increase was primarily due to higher EDG-7500, EDG-15400 and internal personnel-related costs, partially offset by lower discovery and preclinical expenses, and…

• ●an increase of $0.2 million in sevasemten clinical program expenses, which was primarily related to a $1.2 million increase in clinical program expenses in the MESA trial related to increased clinical activity due to patient rollover from the GRAND CANYON trial and $0.8 million increase in the GRAN…

Text removed vs the prior filing · source: 10-Q · 2026-05-07

• Since our inception in 2017, our precision medicine muscle platform has generated several programs to address a variety of muscle diseases. We are advancing multiple clinical-stage programs in muscular dystrophies and severe cardiac diseases, as well as a number of preclinical programs. Our muscular…

• As a late-stage clinical biopharmaceutical company, we are focused on the discovery, development and commercialization of innovative treatments for severe muscle diseases for which there is significant unmet medical need. Guided by our holistic drug discovery approach to targeting the muscle as an o…

• marketable securities of $499.6 million will enable us to fund our planned operating expenses and capital expenditure requirements through at least the next 12 months.

• primarily consist of expenses for the administration of clinical trials as well as manufacturing costs for clinical material supply.

• Comparison of the three months ended March 31, 2026 and 2025

Text added vs the prior filing · source: 10-Q · 2026-08-06

• Risks Related to Our Future Operations Following the Sevasemten Sale

• ●There is no guarantee that we will receive the milestone payments under the Sevasemten Purchase Agreement (as defined below).

• ●We have discretion in the use of the proceeds from the Sevasemten Sale (as defined below) and our choices about the use of proceeds may be ineffective.

• ●We may face new challenges as a smaller, less diversified company.

• ●We may experience operational burdens, disputes or costs in connection with transition services and other post-closing obligations under the Sevasemten Sale.

Text removed vs the prior filing · source: 10-Q · 2026-05-07

• ●We may develop sevasemten and potentially other programs in combination with other therapies, which would expose us to additional risks.

• ●The patient population suffering from Duchenne muscular dystrophy (Duchenne), Becker muscular dystrophy (Becker) and Limb-girdle muscular dystrophy (LGMD) is small and has not been established with precision. If the actual number of patients is smaller than we estimate, our revenue and ability to a…

• ●If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.

• Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. Our operations have consumed substantial amounts of cash since inception, and we expect our expenses to increase i…

• to complete the development and commercialization of our products. Accordingly, we will need to obtain substantial additional funding in order to continue our operations.

Text removed vs the prior filing · source: 10-Q · 2026-05-07

• On March 13, 2026, Alan Russell, Chief Scientific Officer and Director, adopted a Rule 10b5-1 trading arrangement providing for the sale from time to time of up to 200,000 shares of our common stock. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The durati…

• No other directors or “officers,” as defined in Rule 16a-1(f) of the Exchange Act, adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” each as defined in Item 408 of Regulation S-K, during the last fiscal quarter.